A review of endovascular treatment for medium vessel occlusion stroke

Johanna Maria Ospel 1,2, Mayank Goyal 2,3

ABSTRACT

Medium-vessel occlusions (MeVOS), that is, occlusions of the M2/3 middle cerebral artery, A2/3 anterior cerebral artery, and P2/3 posterior cerebral artery segments, account for 25%–40% of all acute ischemic stroke cases. Clinical outcomes of MeVO stroke with intravenous thrombolysis, which is the current standard of care, are moderate at best. With improving imaging technologies and a growing literature, MeVOS are increasingly recognized as a target for endovascular treatment (EVT). For the time being, there is limited but promising evidence for the safety and efficacy of MeVO EVT, and many neurointerventionists are already routinely offering EVT for MeVO stroke, despite the lack of clear guideline recommendations. In this article, we review the evidence on endovascular treatment for MeVO stroke and summarize the available literature on current imaging techniques, commonly used EVT selection criteria, EVT techniques, and outcome assessment for MeVO stroke.

In acute ischemic stroke, blockage of an intracranial artery leads to interruption of blood supply of the brain parenchyma with subsequent ischemia and infarction unless blood flow is restored quickly. Acute ischemic stroke has traditionally been divided into large-vessel occlusion (LVO) stroke, that is, acute stroke due to occlusion of proximal arteries of the anterior circulation (the terminal intracranial internal carotid artery (ICA), M1, or A1 segment), and non-LVO stroke. Around 35%–40% of acute ischemic stroke cases occur due to LVO, while 25%–40% are caused by medium-vessel occlusions (MeVOS). Although it is commonly assumed that outcomes of MeVO strokes are better compared with LVO strokes, due to the more distal occlusion location and less extensive ischemia, cohort studies suggest that outcomes are frequently poor, despite best medical management. Over the past few years, several randomized trials have proven the safety and efficacy of endovascular treatment (EVT) in LVO stroke, while for patients with MeVOS, there is currently no high-level evidence for EVT. But given the high efficacy of EVT in LVO stroke and the substantial morbidity associated with MeVO, EVT is now increasingly performed for MeVO stroke.

DEFINITION OF MEDIUM-VESSSEL OCCLUSIONS

In a recent publication, MeVOS have been defined as occlusions of the M2, M3, A2, A3, P2, or P3 segment. That being said, the distinction between LVOs and MVOs is often challenging. For example, there are various ways to define the border between the M1 segment, which is considered a “large vessel”, and the M2 segment of the middle cerebral artery. Furthermore, because M2 occlusions, particularly those affecting the dominant branch, can cause clinical symptoms identical to M1 occlusions, some authors include M2 occlusions in their definition of LVO. Given the variability in anatomy and clinical symptoms, a multidimensional definition based on morphological features (ie, vessel anatomy and size) and clinical deficits (ie, symptoms that are commensurate with the occluded vessel) may be preferred over a purely anatomical definition.

PRIMARY AND SECONDARY MEVOS

Not all MeVOS are the same: MeVOS can be classified based on their underlying mechanism as either primary or secondary MeVOS. “Primary” MeVOS occur de novo, with etiologies similar to LVOs. “Secondary” MeVOS occur when clot migration or fragmentation of a LVO occurs. This can happen spontaneously or iatrogenically, after intravenous thrombolysis or during EVT. Secondary MeVOS may either represent embolization to new territory, if they are located outside the area that is affected by the primary occlusion, or embolization to distal territory, if they are located within the territory of the proximal occlusion. Another, rare subtype are “concurrent MeVOS”, that is, MeVOS that occur simultaneously with other occlusions. They are likely part of an “embolic shower” or could be due to fragmentation of a more proximal occlusion.

PREVALENCE AND CLINICAL COURSE OF MEVO STROKE

Although it is commonly assumed that outcomes of MeVO strokes are better compared with LVO strokes, due to the more distal occlusion location and less extensive ischemia, a recent analysis from the INTERRSeCT and PRove-IT cohort studies has shown that one out of four patients with MeVO stroke does not achieve functional independence (modified Rankin Scale (mRS) 0–2) at 90 days with current best management, including intravenous thrombolysis if indicated. An excellent outcome (mRS 0–1) is only achieved by half of the patients with MeVO stroke (online supplemental figure 1). These somewhat sobering results emphasize the need for a more effective therapy. Given the overwhelming efficacy of endovascular treatment (EVT) in LVO strokes, it might seem obvious to expand this treatment to MeVO patients as well. Many neurointerventionists already routinely offer EVT in MeVO strokes, particularly in the case of M2
occlusions,7 10 but there is no randomized evidence for MeVO EVT, and it is possible that due to the smaller vessel size, MeVO EVT may yield an increased risk of procedural complications.11 Therefore, the question whether EVT is truly beneficial in the setting of MeVO stroke or not, remains to be answered. Furthermore, the smaller vessel caliber and more distal occlusion location of MeVOS compared with LVOs warrant changes in EVT technique and technology.

In the following, we review the existing literature on treatment indications, imaging selection criteria, and treatment techniques for MeVO EVT as well as clinical outcomes following MeVO EVT. We conclude with an outlook on open questions and ongoing developments.

**SEARCH STRATEGY**

We searched the electronic databases Medline/PubMed, Google Scholar, and EMBASE using the search terms stroke, thrombectomy, endovascular, aspiration, mechanical, small, distal, medium, M2, M3, A2, A3, P2, and P3. We included original research studies, systematic reviews, and meta-analyses which: reported angiographic and/or clinical outcomes of patients with MeVO stroke treated with EVT; included at least five patients; and were published in English. Bibliographies of identified manuscripts were screened for additional relevant studies. The literature search is up-to-date as of 23 November 2020. Tables 1 and 2 provide an overview of the studies and systematic reviews that were identified during the literature search.

**IMAGING PROTOCOLS – HOW TO IMAGE MEVO STROKE?**

Baseline imaging can facilitate EVT treatment decision making in MeVO stroke, or enrollment in a randomized EVT MeVO trial for that matter, by answering the following questions:

1. Is there evidence of intracranial hemorrhage? Just as with LVO stroke, hemorrhagic stroke needs to be ruled out prior to treatment.
2. Is there an acute MeVO? EVT can only be initiated if a target occlusion is visualized.
3. Does that MeVO explain the patient’s deficit (clinical-anatomical correlation, particularly important for secondary MeVOS and concurrent MeVOS in the setting of multiple occlusions)? Right-sided hemiparesis, for example, can be well-explained by a left-sided M2 occlusion, while left-sided hemi-paresis cannot.
4. Is the occlusion likely to recanalize with intravenous thrombolysis? Smaller, permeable thrombi may resolve with intravenous thrombolysis which may influence EVT decision-making.
5. Is the MeVO amenable to safe and fast recanalization using EVT? How technically challenging an operator perceives EVT for a certain MeVO and the availability of dedicated EVT tools designed for MeVOS will also influence the treatment decision and help to set the expectations of the patient and the medical team right.

Since EVT has been established as standard of care in 2015,6 non-invasive neurovascular imaging (CTA or less frequently MR angiography) is recommended for all acute ischemic stroke patients,12 and should thus be obtained in all MeVO patients. In the past, detection of MeVOS on non-invasive imaging has been challenging, but innovative imaging techniques such as multiphase CTA (including color-coded mCTA maps) and CT perfusion have rendered fast and reliable MeVO detection possible13–15 (online supplemental figure 2). Determining the presence of salvageable brain tissue is more challenging in MeVOS compared with LVOs. Established EVT imaging selection criteria that are currently used in LVO stroke, namely Alberta Stroke Program Early CT Score (ASPECTS)≥6,6 intermediate to good collaterals,16 17 and currently established perfusion mismatch/core criteria (eg, ischemic core on CBF maps)18–21 will likely be of little use in MeVO stroke. Due to the more distal occlusion, the ischemic territory will be smaller, and as such, ASPECTS will be generally higher and areas with severe hypoperfusion (“core”) smaller. When assessing collateral status, one would have to assess collaterals solely within the affected territory downstream to the MeVO, which can be challenging, especially in the ACA and PCA territory. So far, no standardized methodology has yet been established. Due to the relative insensitivity and high inter-rater reliability of NCCT in detecting early ischemic changes, and because detecting MeVOS on conventional CTA/MRA images is difficult at times, advanced imaging protocols (CTP and MRI) are often used.

However, accurately determining infarct core and penumbra in MeVO stroke may be challenging or not possible at all, as recent literature suggests that we currently lack the ability to precisely delineate infarct “core” with routinely used imaging methods.22 More importantly, delineating ischemic core and penumbra may not even be necessary, as past early time window LVO trials failed to show any volume cut-off below which EVT was no longer beneficial, and current EVT guidelines for LVO patients in the early time window therefore exclusively rely on NCCT ASPECTS to estimate the degree of irreversible tissue damage.6 That being said, using ASPECTS in MeVO stroke may be problematic, since the anterior and posterior cerebral artery territories are not represented at all, and even in middle cerebral artery MeVOS, the ASPECTS range will be relatively small, since the internal capsule, lentiform, and caudate are unlikely to be affected, and of the cortical 6 regions, only few will be affected. Thus, for a typical M3 occlusion, ASPECTS may be either 8, 9, or 10.

Most of the MeVO EVT studies we identified used a CT-based imaging protocol, and approximately half of them included CT perfusion as part of the standard protocol, regardless of the time frame, and some reported MRI-based protocols with DWI ± PWI sequences (table 2). Studies that relied only on NCCT and single-phase CTA were mostly subgroup analyses from randomized LVO trials and LVO registries,23 24 that is, M2 occlusions were a small minority of all cases. Many studies simply transferred the perfusion threshold,25 and ASPECTS26 27 cut-offs that are used for LVO strokes to their MeVO patient sample, which may be suboptimal for MeVO patient selection. Only a few studies adapted imaging selection criteria and used, for example, a higher ASPECTS cut-off.28 29 Table 3 provides an overview of different MeVO imaging paradigms. Future studies should aim to develop MeVO-specific imaging selection criteria for EVT.

**CLINICAL EVT SELECTION CRITERIA FOR MEVO EVT**

Just as there are no uniform imaging criteria for EVT patient selection in MeVO strokes, there is also no consensus on clinical selection criteria. Several MeVO EVT studies used an NIHSS threshold of ≥6,23–26 as it is currently recommended for LVO strokes.6 However, a recent analysis from prospective cohort studies has shown that 1/3 of MeVO stroke patients have a baseline NIHSS <6. One study specifically stated that they included patients “with NIHSS ≥6 or disabling deficit”,20 and another one lowered the NIHSS cut-off of 5 instead of 6,29 which seems more appropriate, considering that one out of three patients with untreated supposedly “mild” strokes (NIHSS <5) will not be functionally independent at 90 days.31 Indeed, in a recent survey, most physicians stated that they would offer EVT for
<table>
<thead>
<tr>
<th>First Author</th>
<th>Year</th>
<th>Study type</th>
<th>N with MeVO EVT</th>
<th>NIHSS (median/mean)</th>
<th>ASPECTS (median/mean)</th>
<th>Imaging modality used</th>
<th>Treatment criteria</th>
<th>MeVO type</th>
<th>Technique used</th>
<th>Anesthesia</th>
<th>Angiographic outcome</th>
<th>Clinical outcome</th>
<th>sICH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Romano et al 2020</td>
<td>27</td>
<td>SC</td>
<td>157</td>
<td>3/17</td>
<td>9</td>
<td>NCCT+CTA+CTP</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Haussen et al 2020</td>
<td>18</td>
<td>SC</td>
<td>37</td>
<td>15</td>
<td>15</td>
<td>NCCT+CTA+CTP</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Adhaneeyasakul et al 2020</td>
<td>22</td>
<td>SC</td>
<td>46</td>
<td>19</td>
<td>17</td>
<td>NCCT+CTA+CTP</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Jiang et al 2019</td>
<td>25</td>
<td>SC</td>
<td>25</td>
<td>15</td>
<td>15</td>
<td>NCCT+CTA+CTP</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Compagne et al 2019</td>
<td>24</td>
<td>MC</td>
<td>244</td>
<td>14</td>
<td>14</td>
<td>NCCT+CTA</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Gory et al 2019</td>
<td>26</td>
<td>MC</td>
<td>288</td>
<td>16</td>
<td>16</td>
<td>NCCT+CTA</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Navia et al 2019</td>
<td>27</td>
<td>SC</td>
<td>6</td>
<td>12.5</td>
<td>12.5</td>
<td>NCCT+CTA</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Menon et al 2019</td>
<td>28</td>
<td>MC</td>
<td>50</td>
<td>13</td>
<td>13</td>
<td>NCCT+CTA</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Coutinho et al 2019</td>
<td>29</td>
<td>SC</td>
<td>69</td>
<td>18.1</td>
<td>8</td>
<td>NCCT+CTA+CTP</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Gory et al 2018</td>
<td>30</td>
<td>RCT</td>
<td>79</td>
<td>13.4</td>
<td>13.4</td>
<td>NCCT+CTA+CTP</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
<tr>
<td>Sarraj et al 2016</td>
<td>31</td>
<td>MC</td>
<td>288</td>
<td>16</td>
<td>16</td>
<td>NCCT+CTA</td>
<td>Symptom onset ≤350 pixels MeVO (absence of concurrent LVO)</td>
<td>M2</td>
<td>DA, SR</td>
<td>CS</td>
<td>TICI 2b: 95%</td>
<td>mRS 0–2: 49%</td>
<td>11%</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>First Author Year</th>
<th>Study type</th>
<th>N with MeVO</th>
<th>NIHSS (median/mean)</th>
<th>Imaging modality used</th>
<th>Treatment criteria</th>
<th>MeVO type</th>
<th>Technique used</th>
<th>Anesthesia</th>
<th>Angiographic outcome</th>
<th>Clinical outcome</th>
<th>sICH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nakano et al 2020</td>
<td>MC</td>
<td>51</td>
<td>17</td>
<td>8</td>
<td>-</td>
<td>MD</td>
<td>DA, SR</td>
<td>-</td>
<td>TICI 2b/3: 84%</td>
<td>mRS 0–2: 49%</td>
<td>3%</td>
</tr>
<tr>
<td>Altenbernd et al 2018</td>
<td>SC</td>
<td>58</td>
<td>15</td>
<td>9</td>
<td>NCCT+CTA+CTP</td>
<td>Age ≥18 NIHSS ≥6 ASPECTS ≥8</td>
<td>MD, M3</td>
<td>DA, GA</td>
<td>-</td>
<td>TICI 2b/3: 100% TICI 3: 83%</td>
<td>mRS 0–2: 95% mRS 0–1: 86% mRS 0: 35%</td>
</tr>
<tr>
<td>Crockett et al 2019</td>
<td>SC</td>
<td>14</td>
<td>8</td>
<td>9</td>
<td>-</td>
<td>A2, A3, P2, M3, SCA</td>
<td>DA</td>
<td>-</td>
<td>-</td>
<td>TICI 2b/3: 100% TICI 2c/3: 100% TICI 3: 91%</td>
<td>mRS 0–2: 63% mRS 0–1: 50% mRS 0: 43%</td>
</tr>
<tr>
<td>Bhogal et al 2017</td>
<td>SC</td>
<td>106</td>
<td>12</td>
<td>9</td>
<td>NCCT+CTA or MRI</td>
<td>-</td>
<td>MD, SR</td>
<td>-</td>
<td>TICI 2b/3: 91% TICI 3: 69%</td>
<td>mRS 0–2: 53% mRS 0–1: 45% mRS 0: 24%</td>
<td>5%</td>
</tr>
<tr>
<td>de Castro Afonso et al 2019</td>
<td>SC</td>
<td>30</td>
<td>16</td>
<td>9</td>
<td>NCCT+CTA</td>
<td>Symptom onset≥6 hour or CTP mismatch if symptom onset 6–24 hour NIHSS≥6 ASPECTS≥6</td>
<td>MD</td>
<td>DA, SR, combination CS, GA</td>
<td>-</td>
<td>TICI 2b/3: 90% TICI 2c/3: 60% TICI 3: 53%</td>
<td>mRS 0–2: 50% mRS 0–1: 23% mRS 0: 17%</td>
</tr>
<tr>
<td>Grieb et al 2019</td>
<td>SC</td>
<td>52</td>
<td>12</td>
<td>-</td>
<td>NCCT+CTA</td>
<td>NIHSS ≥6 or aphasia Absence of large infarction</td>
<td>MD</td>
<td>DA, SR, combination CS, GA</td>
<td>-</td>
<td>TICI 2b/3: 91% TICI 3: 65%</td>
<td>mRS 0–2: 56%</td>
</tr>
<tr>
<td>Pérez-García et al 2020</td>
<td>SC</td>
<td>102</td>
<td>16</td>
<td>9</td>
<td>-</td>
<td>M2, M3, Any ACA Any PCA</td>
<td>SR, combination CS, GA</td>
<td>-</td>
<td>TICI 2b/3: 50% (SR) vs 64% (combination) TICI 2c/3: 34% (SR) vs 57% (combination)</td>
<td>mRS 0–2: 53 (SR) vs 51% (combined)</td>
<td>13% (SR) vs 2% (combination)</td>
</tr>
<tr>
<td>Haussen et al 2020</td>
<td>SC</td>
<td>22</td>
<td>17</td>
<td>8</td>
<td>-</td>
<td>M2</td>
<td>Combination</td>
<td>-</td>
<td>TICI 2b/3: 84% TICI 3: 64%</td>
<td>mRS 0–2: 40%</td>
<td>-</td>
</tr>
<tr>
<td>Pfaff et al 2016</td>
<td>SC</td>
<td>30</td>
<td>18</td>
<td>9</td>
<td>DWI+MRA+ PWI or NCCT+CTA+CTP</td>
<td>Symptom onset ≥8 hour NIHSS ≥8 ASPECTS ≥6</td>
<td>A2, A3, A4</td>
<td>SR, CS, GA</td>
<td>-</td>
<td>TICI 2b/3: 73%</td>
<td>mRS 0–2: 37%</td>
</tr>
<tr>
<td>Styczen et al 2020</td>
<td>MC</td>
<td>15</td>
<td>13</td>
<td>10 (pcASPECTS)</td>
<td>-</td>
<td>SCA, AICA, PICA</td>
<td>SR, DA, combination IA IPA</td>
<td>-</td>
<td>TICI 2b/3: 88% TICI 3: 31%</td>
<td>mRS 0–2: 50% mRS 0–1: 29% mRS 0: 7%</td>
<td>-</td>
</tr>
</tbody>
</table>

Note: MC = multi center, SC = single center, EVT = endovascular treatment, MeVO = medium vessel occlusion stroke, NIHSS = National Institutes of Health Stroke Scale, pcASPECTS = posterior circulation Alberta Stroke Program Early CT Score, CTA = CT angiography, NCCT = non contrast head CT, DWI = diffusion weighted imaging, CTP = CT perfusion, DA = direct aspiration, SR = stent retriever, IA 1PA = intra arterial alteplase, CS = conscious sedation, GA = general anesthesia, SCA = superior cerebellar artery, AICA = anterior inferior cerebellar artery, PICA = posterior inferior cerebellar artery, TICI = Thrombolysis in Cerebral Infarction Score, mRS = modified Rankin Score, sICH = symptomatic intracranial hemorrhage.
LVO patients with low NIHSS. Whether a patient is eligible for intravenous thrombolysis or not also seems to play an important role in MeVO EVT decision-making. More than 50% of physicians would perform EVT in M3, A2, and P2 occlusions if the patient is ineligible for intravenous thrombolysis, but when intravenous thrombolytics can be safely administered, the willingness to proceed with EVT is substantially lower. For now, until randomized trial data become available, the decision to treat or not to treat a MeVO will remain a subjective one that is influenced by many factors, including patient preferences, eligibility for intravenous thrombolysis, and operator skills. Treatment decision-making is further complicated by the variety of clinical symptoms MeVO patients can present with, which are dependent on the eloquence of the affected area. A patient with a right-sided small branch anterior M2 occlusion, for example, may barely suffer from any deficits, but another patient suffering from a similar sized left-sided M2 occlusion may present with severe aphasia. Furthermore, new thrombolytic agents such as Tenecteplase and neuroprotectants such as Nerinertide could improve the prognosis of MeVO stroke with conservative management and thereby also influence treatment decision-making in MeVO EVT.

**THROMBECTOMY TECHNIQUE – HOW TO PERFORM EVT IN MEVO STROKE?**

Several challenges emerge when performing EVT for MeVOS stroke. For the time being, we don’t know how high the risk of vasospasm and dissection is when the catheter size matches or exceeds the vessel diameter, which can happen with large-bore aspiration catheters in MeVOS. Medium-sized vessels can be too small to harbor a regular-sized distal access catheter (DAC), as most of the currently used DACs are 5–6F in diameter. Another problem is the DAC often gets stuck at the ledge of a bifurcation point such, as the M1 bifurcation, but there are wedge-shaped microcatheters available to overcome this ledge effect. Furthermore, using a primary combined approach (ie, the combination of stent retriever, DAC, and balloon guide catheter), and advancing the system in a tri-axial manner, as it is commonly done for LVOs, may not be possible because of insufficient catheter length and diameter discrepancies. For example, using a longer DAC to access an M3 occlusion may not allow for a small enough and long enough microcatheter capable of deploying a stent. Thus, currently, the microwire and microcatheter are often introduced without a DAC. Once the microcatheter is in place, the stent can be deployed and the microcatheter removed before the distal access catheter is navigated to the site of occlusion (so-called “blind exchange mini-pinning technique”). However, this is probably a transient problem, as many of the newer stent retrievers can be deployed through a 0.017 microcatheter and more microcatheters are now available in 160 cm length. On the other hand, numerous authors reported promising results of primary aspiration as the first-line approach in MeVO stroke, which may constitute an equally effective alternative to stent retriever-based techniques. A comprehensive and unbiased comparison of different MeVO EVT techniques is currently not possible, since most studies are small, focus on specific devices, and a comparator group is often lacking. Furthermore, the literature on MeVO EVT techniques is biased, with onset-to-treatment times being on average much shorter in studies that used primary aspiration compared with those in which stent retrievers were used. Of note, MeVO EVT techniques and technologies are constantly evolving, and with MeVOS increasingly being targeted by neurointerventionalists, it is likely that treatment devices that are specifically tailored to MeVOS will be developed in the near future.

A substantial number of LVOs are treated without the use of general anesthesia (GA). Although randomized trials show equivalent or even better outcomes with GA vs conscious sedation,
data from the HERMES collaboration\(^{40}\) and individual EVT trials\(^{41}\) show worse outcomes with GA. It is possible that the use of GA will substantially increase when performing MeVO EVT, given the need for an excellent roadmap to get access to the relatively distally located clot. In addition, the anatomical variability is much higher in distal vessels. Sometimes, the MeVO may be right at the origin of a vessel branch, which requires the operator to blindly explore the site of the occlusion very gently in order to find the relevant vessel origin, which is much easier under GA, when patient movement is completely eliminated. Thus, the impact of an increased use of GA on functional outcome will need to be better understood.

**OUTCOME ASSESSMENT IN MEVO EVT**

**Clinical outcomes**

In MeVO strokes the area that is affected by ischemia is smaller than in LVO strokes. Thus, one would intuitively expect clinical outcomes to be better. Most studies that were identified in the literature search reported “good outcome”, defined as mRS 0–2 at 90 days, as primary outcome (table 1). Given the overall better prognosis, it seems however worthwhile to consider a more restrictive outcome measure such as “excellent outcome”, i.e. mRS 0–1, or mRS shift analysis. Indeed, this has been recognized by several authors, who reported mRS 0–1 or proportions of patients in each mRS category in addition to mRS 0–2 (table 1).

It is important to note that deficits such as isolated bulbia (due to A2/3 occlusion), alexia and agraphia (due to M2/3 occlusions), or quadrantanopia (due to P2/3 occlusion) are not well captured in the NIHSS and mRS. Not only are those scales limited in their granularity, they are also heavily focused on motor function and thus unable to capture the more subtle personality changes and domain-specific impairment that often play a dominant role in MeVO stroke-related disability.

**Angiographic outcomes**

In most MeVO EVT studies, angiographic outcomes are reported as “successful reperfusion”, that is, TICI 2b/3, analogous to reperfusion assessment in LVO stroke, although several studies reported TICI 3 and/or TICI 2c/3 reperfusion in addition to TICI 2b/3 rates (table 1). Reporting successful reperfusion (TICI 2b/3) only is problematic, given that MeVOS in the anterior and posterior cerebral artery territory are not reflected in TICI at all, and patients with distal M2 or M3 occlusions will frequently have TICI 2b at baseline. There is currently no satisfactory reperfusion grading system tailored to MeVO stroke. Crockett et al made an interesting attempt in this regard: in addition to the “regular” TICI, they used a modified TICI, which focused solely on the territory affected by the MeVO, with a scoring system identical to the standard TICI system (1, 2a, 2b, 2c, 3).\(^{33}\) Figure 1 shows a proposed modified eTICI scoring system for
Ischemic stroke

Suggested modified eTICI classification for MeVOs in the anterior (MeVO-A-TICI: A), middle (MeVO-M-TICI: B) and posterior (MeVO-P-TICI: C) cerebral artery. Blue overlays in (A1), (B1), and (C1) indicate the “denominator”, that is, the territory downstream of the occlusion that serves as a comparator. Complete reperfusion of the territory marked in blue would correspond to an eTICI score of 3. Reperfusion contained to territory marked with red overlays in (A2), (B2), and (C2) would indicate a MeVO-A-TICI, MeVO-M-TICI, and MeVO-P-TICI score of 2A, that is, reperfusion of less than 50% of the initially affected territory. Reperfusion contained to territory marked with yellow overlays in (A3), (B3), and (C3) would indicate an MeVO-A-TICI, MeVO-M-TICI, and MeVO-P-TICI score of 2B, that is, reperfusion of 50%–90% of the initially affected territory. Reperfusion contained to territory marked with red overlays in (A4), (B4), and (C4) would indicate an MeVO-A-TICI, MeVO-M-TICI, and MeVO-P-TICI score of 2c, that is, near-complete reperfusion/ reperfusion of less than 90%–99% of the initially affected territory.

OUTCOMES FOR EVT IN PRIMARY VS. SECONDARY MEVOS

Most of the literature published on MeVO EVT does not distinguish between primary and secondary MeVOS. But in particular the effect of “rescue” EVT in procedure-related secondary MeVOS is of great interest for neurointerventionalists, since peri-procedural embolization of clot fragments is a common phenomenon. Embolization causing anterior cerebral artery occlusion, for example, has been observed in more than 10% of LVO EVT procedures, especially in cases with terminal ICA occlusion, in which the clot segment extending into the ACA might get “guillotined off” by the distal aspiration catheter or stent retriever. Since the infarcted area will often be larger in secondary MeVOS, one would assume clinical outcomes to be worse compared with primary MeVO strokes. However, Grossberg et al, who reported post-EVT outcomes for primary and iatrogenic (EVT-induced) secondary MeVOS separately, found similar recanalization results and even slightly better clinical outcomes in patients with secondary MeVOS, despite more severe symptoms at baseline. Future studies on MeVO EVT should aim to capture information on MeVO types, and report results stratified for primary vs secondary MeVOS.

CONCLUSION AND OUTLOOK

With improving imaging technologies and a growing body of literature, MeVOS are being increasingly recognized as a target for EVT. Outcomes with intravenous thrombolysis, which is the current standard of care, are moderate at best and many patients are not eligible for thrombolytic treatment at all. At the present time, there is limited but promising evidence for the safety and efficacy of MeVO EVT. Many interventionists are already routinely treating primary as well as secondary MeVOS, that is, emboli into distal vessels during EVT for LVO stroke. However, standardized imaging protocols, treatment indication criteria, and unbiased comparisons of different EVT techniques for MeVOS are lacking. At the same time, imaging tools and particularly MeVO EVT techniques are rapidly evolving. A randomized controlled trial seems unavoidable in order to establish MeVO EVT as standard of care.

Twitter Johanna Maria Ospel @johanna_ospel and Mayank Goyal @mayank_G0

Acknowledgements The authors want to thank Basti Uhlmann for his help in designing the figure.

Contributors Both authors were involved in drafting and critical revisions of the manuscript.
Ischemic stroke

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests MG is a consultant for Medtronic, Stryker, Microvention, GE Healthcare, Menitec.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omission arising from translation and adaptation or otherwise.

ORCID iDs
Johanna Maria Ospel http://orcid.org/0000-0003-0029-6764
Mayank Goyal http://orcid.org/0000-0001-9060-2109

REFERENCES
Ischemic stroke


### SUPPLEMENTARY MATERIAL

A Review of Endovascular Treatment for Medium Vessel Occlusion Stroke

<table>
<thead>
<tr>
<th>90 day mRS (n = 258)</th>
<th>25.6</th>
<th>24.4</th>
<th>17.4</th>
<th>10.5</th>
<th>7.8</th>
<th>5.4</th>
<th>8.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>90 day mRS without prox. M2 occlusions (n = 184)</th>
<th>29.9</th>
<th>26.1</th>
<th>18.5</th>
<th>10.3</th>
<th>6.5</th>
<th>2.2</th>
<th>6.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>90 day mRS baseline NIHSS &lt; 12 only (n = 196)</th>
<th>31.1</th>
<th>27.6</th>
<th>19.9</th>
<th>9.7</th>
<th>5.1</th>
<th>3.1</th>
<th>3.6</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Suppl. figure 1:** Distribution of 90 day mRS in patients with MeVO strokes (data from the PRove-IT and INTERRSeCT studies, published with permission from AHA, 2020) \(^1\text{,}^2\) (A). mRS categories are shown in ascending order from left to right. Numbers indicate the percentage of patients in one category of the mRS. The mRS distribution was similar after excluding patients with proximal M2 occlusions (B), and after excluding patients with baseline NIHSS > 12 (C).
Figure 2 (published with permission from ASNR, 2020): Patient with acute left-hemispheric symptoms (weakness of the right arm and aphasia). Multiphase CTA (arterial phase shown in A, peak-venous and late-venous phases shown in B and C) show delayed contrast washout in the left perisylvian region, which raises the suspicion of a medium vessel occlusion. On single phase CTA (D), it is very challenging to see the occlusion or any difference in collateral filling. Color-coded time variant mCTA summation maps facilitate the diagnosis further, as the abrupt change in vessel color on the mCTA summation map is more obvious than changes in enhancement on greyscale images (color-coded mCTA summation map (GE FastStrokeTM) shown in E: vessels with maximum enhancement in the arterial phase are shown in red, those enhancing in the peak-venous and late-venous phases are shown in green and blue). The time-to-peak map (courtesy: Wu Qiu, PhD) that is derived from mCTA (F) shows a clear change of color in the affected parenchyma and are another possibility to fast and reliably detect MeVOs.
References

